A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-experienced Adult Subjects.
Latest Information Update: 08 Aug 2019
At a glance
- Drugs TV 003 (Primary) ; TV 005 (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- 23 Oct 2012 Planned end date 1 May 2015 added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 18 Jan 2012 New trial record